Arjo, a market-leading supplier of medical devices and solutions, has entered into a Joint Marketing Agreement with BBI LLC (Bruin Biometrics), a US based technology company, who are committed to modernising health care with biometric sensor technology for the early risk assessment and monitoring of chronic, preventable conditions in collaboration with clinicians.
Arjo and BBI will work together for the promotion of a Pressure Ulcer (PU) Prevention Solution Set combining the BBI SEM Scanner and Arjo pressure ulcer interventions, including specialised beds and surfaces resulting in an offering that provides real preventive healthcare for patients at risk of pressure ulcers.
A recent NHSI1 report identified that between 1700-2000 patients develop a PU per month and that treating pressure ulcers costs the NHS more than £3.8m per month.
“This agreement is very much in line with our strategy to become a true solutions provider in the prevention and treatment of pressure ulcers. We have created a fantastic opportunity to develop innovative go to market models that can really make a difference for both patients and healthcare professionals” says William Dorrian, Director, Arjo Corporate Development & Projects
Arjo‚Äôs Pressure Ulcer & Injury Prevention Solutions enable healthcare professionals to effectively prevent and treat pressure ulcers & injuries. Our integrated clinical approach and proprietary microclimate management technology improve patient outcomes and reduce healthcare costs in all care settings.
The SEM Scanner is a hand-held, portable, skin tissue assessment device that measures sub-epidermal moisture, an invisible precursor to the development of pressure damage. The SEM Scanner has been found, when used as an adjunct to current standard of care, to detect tissue damage on the sacrum and heels 5 days (median)2 before it becomes visible on the skin surface.
Colin Priestley, MD EMEA BBI (Europe) Ltd stated “BBI is delighted to work with Arjo a recognised health care solutions provider. This agreement, incorporating the innovative technology of the SEM Scanner, will enable healthcare practitioners, across Great Britain, to further develop their prevention protocols as they continue to strive for pressure ulcer incidence reduction.”
The Joint Marketing Agreement commenced 3rd August 2018 and, according to the terms of the agreement, Arjo & BBI will collaborate within the territory of Great Britain.
For further information, please contact:
Kate Hancock, VP Marketing and Clinical Communications, North America and EMEA
Tel: +44 7827 315347
Martyn Elcocks, Strategic Marketing Director, UKI
Tel: +44 1582 745575
BBI (Bruin Biometrics), is a pioneer in modernising health care with biometric sensor technology for early risk assessment and monitoring of chronic, preventable conditions in collaboration with clinicians. BBI has been the recipient of multiple awards with recognition from organisations such as Journal of Wound Care, Health Service Journal and Frost & Sullivan. BBI is based in Los Angeles and maintains a European office in Manchester, UK.
For additional information, visit www.sem-scanner.com
At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has approximately 6,000 employees worldwide and customers in over 100 countries. In 2017, Arjo sales amounted to approximately SEK 7.7 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malm√∂, Sweden. Everything we do, we do with people in mind. www.arjo.com
1. NHS Improvement, (June 2018), Pressure Ulcer: revised definition and measurement. Summary and Recommendations. Publication Code CG 73/18
2. Okonkwo H. Milne et al. (2018) Evaluation of a novel device using capacitance of the detection of early pressure ulcers (PU), a multi-site longitudinal study. Accepted and presented at NPUAP 2018. Manuscript submitted for publication
Have questions about our company, products or pipeline? We'd like to hear from you.